TD101

Pachyonychia Congenita Project · Phase 1 active Small molecule

At a glance

Generic name	TD101
Sponsor	Pachyonychia Congenita Project
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TD101 CI brief — competitive landscape report
TD101 updates RSS · CI watch RSS
Pachyonychia Congenita Project portfolio CI